2. Academic Validation
  3. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors

Imidazo[1,2-a]pyrazines as novel PI3K inhibitors

  • Bioorg Med Chem Lett. 2012 Mar 1;22(5):1874-8. doi: 10.1016/j.bmcl.2012.01.074.
Sonia Martínez González 1,  Ana Isabel Hernández,  Carmen Varela,  Sonsoles Rodríguez-Arístegui,  Rosa María Alvarez,  Ana Belén García,  Milagros Lorenzo,  Virginia Rivero,  Julen Oyarzabal,  Obdulia Rabal,  James R Bischoff,  Maribel Albarrán,  Antonio Cebriá,  Patricia Alfonso,  Wolfgang Link,  Jesús Fominaya,  Joaquín Pastor
Affiliations

Affiliation

  • 1 Experimental Therapeutics Program, Spanish National Cancer Research Centre (CNIO). C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
PMID: 22325943 DOI: 10.1016/j.bmcl.2012.01.074
Abstract

Phosphoinositide-3-kinase (PI3K) is an important target for Cancer therapeutics due to the deregulation of its signaling pathway in a wide variety of human cancers. We describe herein a novel series of imidazo[1,2-a]pyrazines as PI3K inhibitors.

Figures
Products